Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

Article Hematology

Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States

Amer M. Zeidan et al.

Summary: In comparing IC and VEN-AZA for AML treatment, IC showed higher rates of complete remission and hematopoietic stem cell transplant than VEN-AZA, but no significant differences were observed in overall survival or relapse-free survival.

ANNALS OF HEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

添加到收藏夹

Article Hematology

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality

Abhishek Maiti et al.

Summary: Hypomethylating agents with venetoclax have become a new standard for older/unfit patients with AML. Comparisons between HMA with venetoclax and intensive chemotherapy in both fit and unfit patients show that DEC10-VEN therapy offers better outcomes, particularly in those at high-risk of treatment-related mortality.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

Arie Apel et al.

Summary: Combination therapy of venetoclax with hypomethylating agents or low dose cytarabine has shown promising efficacy and safety in AML patients unfit for intensive therapy. The treatment resulted in high rates of complete remission, with adverse karyotype and ECOG performance status being significant predictors of outcomes. Treatment was generally well-tolerated, with tumor lysis syndrome occurring in a minority of patients.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)

Amandeep Salhotra et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Mohamed L. Sorror et al.

Summary: The study found that less-intensive induction therapies in older patients with AML were associated with higher mortality risks, but after adjusting for age, physician-assigned KPS, and chance of cure, mortality risks and QOL were similar. Patients receiving less-intensive therapies had shorter lengths of hospitalization. Randomized trials are needed to better assess the value of less-intensive and intensive therapies in older or medically infirm patients.

BLOOD (2021)

添加到收藏夹

Article Hematology

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

Evan M. Cherry et al.

Summary: Venetoclax plus azacitidine is the standard treatment for newly diagnosed AML patients who cannot undergo intensive chemotherapy. Patients eligible for intensive chemotherapy sometimes opt for ven/aza instead. In a retrospective analysis, patients receiving ven/aza had a higher response rate but shorter median overall survival compared to those receiving IC. Certain variables, such as age, AML subtype, and gene mutations, were identified that favored response to one treatment over the other.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology